Research News

BrightFocus Foundation, a nonprofit and premier source of research funding to defeat Alzheimer’s, macular degeneration, and glaucoma, today was acknowledged as the catalyst behind a major advance in drug development for Alzheimer’s disease.

Ruchira Singh and colleagues at the University of Rochester and worldwide have shown that even rare forms of macular degeneration develop in ways similar to AMD, with drusen formation and extracellular proteins. The goal ahead: effective early treatment approaches.

Kip Connor, PhD, with funding from Macular Degeneration Research (MDR), has lead a team of experts to discover an important role of immune cells that regulate, and could potentially stop, abnormal blood vessel growth in advanced age-related macular degeneration (AMD).

Francis Hanes, PhD, is using his knowledge of biophysics to advance Alzheimer’s imaging and achieve earlier diagnosis. Read about his BrightFocus-funded research.

Learn about an exciting citizen science project receiving support from the BrightFocus Alzheimer’s Disease Research program; the first crowd-sourced effort to gather data to help end Alzheimer’s disease.

Top U.S. scientists are concerned that eye and vision health are relatively absent from national health priority lists. AMD, in particular, is rising..

An experimental drug, consisting of cells manufactured and implanted in the eye to stimulate optic nerve growth and activity, could be an entirely new way of fighting glaucoma.